Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hodgson

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Pharmacoeconomics|November 23, 2018
Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology AppraisalLindsay Claxton, Joanne O'Connor, Nerys Woolacott, et al.
Pharmacoeconomics|October 10, 2018
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology AppraisalLindsay Claxton, Joanne O'Connor, Nerys Woolacott, et al.
Environmental Research|July 22, 2023
Impacts of net zero policies on air quality in a metropolitan area of the United Kingdom: Towards world health organization air quality guidelinesJian Zhong, James Robert Hodgson, William James Bloss, et al.
Organic & Biomolecular Chemistry|August 22, 2003
A stereodivergent, two-directional synthesis of stereoisomeric C-linked disaccharide mimeticsMichael Harding, Robert Hodgson, Tahir Majid, et al.
Pharmacoeconomics|October 28, 2016
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United KingdomLindsay Claxton, Robert Hodgson, Matthew Taylor, et al.
Pharmacoeconomics|March 26, 2017
Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPhilip Morgan, Nerys Woolacott, Mousumi Biswas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2022
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United KingdomLindsay Claxton, Matthew Walton, Sahar Sharif-Hurst, et al.
Pharmacoeconomics|December 3, 2024
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group PerspectiveSarah J Nevitt, David M Phillippo, Robert Hodgson, et al.
Health Technology Assessment (Winchester, England)|February 9, 2026
Artificial Intelligence technologies for assessing skin lesions for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: early value assessmentMatthew Walton, Alexis Llewellyn, Eleonora Uphoff, et al.
Organic & Biomolecular Chemistry|August 30, 2003
Exploiting predisposition in the stereoselective synthesis of mono-, bi- and tetracyclic oxygen heterocycles: equilibration between, and trapping of, alternative di- and tetraacetalsStephen Bartlett, Robert Hodgson, Joanne M Holland, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Pharmacoeconomics|November 23, 2018
Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology AppraisalLindsay Claxton, Joanne O'Connor, Nerys Woolacott, et al.
Pharmacoeconomics|October 10, 2018
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology AppraisalLindsay Claxton, Joanne O'Connor, Nerys Woolacott, et al.
Environmental Research|July 22, 2023
Impacts of net zero policies on air quality in a metropolitan area of the United Kingdom: Towards world health organization air quality guidelinesJian Zhong, James Robert Hodgson, William James Bloss, et al.
Organic & Biomolecular Chemistry|August 22, 2003
A stereodivergent, two-directional synthesis of stereoisomeric C-linked disaccharide mimeticsMichael Harding, Robert Hodgson, Tahir Majid, et al.
Pharmacoeconomics|October 28, 2016
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United KingdomLindsay Claxton, Robert Hodgson, Matthew Taylor, et al.
Pharmacoeconomics|March 26, 2017
Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPhilip Morgan, Nerys Woolacott, Mousumi Biswas, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 2, 2022
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United KingdomLindsay Claxton, Matthew Walton, Sahar Sharif-Hurst, et al.
Pharmacoeconomics|December 3, 2024
Application of Multi-level Network Meta-Regression in the NICE Technology Appraisal of Quizartinib for Induction, Consolidation and Maintenance Treatment of Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukaemia: An External Assessment Group PerspectiveSarah J Nevitt, David M Phillippo, Robert Hodgson, et al.
Health Technology Assessment (Winchester, England)|February 9, 2026
Artificial Intelligence technologies for assessing skin lesions for referral on the urgent suspected cancer pathway to detect benign lesions and reduce secondary care specialist appointments: early value assessmentMatthew Walton, Alexis Llewellyn, Eleonora Uphoff, et al.
Organic & Biomolecular Chemistry|August 30, 2003
Exploiting predisposition in the stereoselective synthesis of mono-, bi- and tetracyclic oxygen heterocycles: equilibration between, and trapping of, alternative di- and tetraacetalsStephen Bartlett, Robert Hodgson, Joanne M Holland, et al.
Pageof 7